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tanning, or family history of skin cancer. Physical examination
revealed a 0.5 cm area of induration on the right labia majora. No
ulceration or hyperpigmentation was seen in the skin. The rest of
the genital and pelvic exam was reported to be normal. An excision-
al biopsy of the area was performed. Histopathologic evaluation
revealed a multilobular tumor arising from the epidermis, composed
of basaloid epithelial cells, demonstrating peripheral palisading, stro-
mal retraction, pleomorphism, single cell necrosis, and cytologic atypia,
typical of basal cell carcinoma, nodular type, tumor stage T1NXMXIntroduction
In the United States, non-melanoma skin cancer (NMSC) accounts
for over a million new cancer cases annually (National Cancer
Institute and US National Institute of Health, 2010), 75% of which
are basal cell carcinoma (BCC), making it the most common human
malignancy (Miller andWeinstock, 1994). Although BCC is frequently
seen in white patients on sun-exposed sites, this NMSC may arise on
non-sun-exposed sites, including the perianal and genital regions
(De Giorgi et al., 2005; Pisani et al., 2006; Breen et al., 1975). Vulvar
BCC accounts for less than 1% of all BCC and less than 5% of all vulvar
cancers (Pisani et al., 2006).
We report on a case of a 20-year-old African-American female
with vulvar BCC. In addition to the uncommon location, this presenta-
tion of BCC is also exceptional due to the patient's young age and race.Case report
A 20-year-old nulligravid African-American presented in September
2010 with a 9 month history of a lump on the right side of her
vulva. She denied any vulvar itching, pain, bleeding or changes inisclose.
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-ND license .(Figs. 1 and 2). In October 2010, she underwent a wide local excision
with a 1 cm margin surrounding the site of previous excision. The
ﬁnal pathology revealed surgical site changes, with no residual basal
cell carcinoma. Extension into subcutis and underlying structures was
not identiﬁed on the original nor wide local excision specimens. Com-
plete dermatologic evaluation revealed a well-healed incision site on
the right labia majora. The remainder of the vulva was unremarkable,
and there was no palpable inguinal adenopathy on physical exam. The
remainder of her skin exam was unremarkable, with the exception of
scattered 1–3 mm benign-appearing nevi. There were no stigmata of
genetic syndromic predisposition for basal cell carcinoma. The patient
was without evidence of disease at 10 months of follow-up.Discussion
Vulvar BCC is a rare tumor, with only approximately 250 cases
reported in the literature (Pisani et al., 2006). The ages at presenta-
tion have been reported to range from 34 to 96 years, with an average
age of 70 years (De Giorgi et al., 2005; Pisani et al., 2006; Breen et al.,
1975; Mulayim et al., 2002; Benedet et al., 1997). To date, this is the
youngest patient reported to have vulvar BCC. The etiology is un-
known but associated risk factors include exposure to ultraviolet ra-
diation and lighter complexion (De Giorgi et al., 2005; Feakins and
Lowe, 1997). However, unlike BCC of the head and neck where ultra-
violet radiation is frequently implicated as a causative agent, expo-
sure to ultraviolet radiation does not provide a plausible
explanation for the etiology of BCC in sun-shielded areas of the
body, such as the vulva (De Giorgi et al., 2005; Mulayim et al.,
2002; Benedet et al., 1997; Feakins and Lowe, 1997). Agents that
have been implicated include ionizing radiation, arsenic, immuno-
suppressive states, hereditary skin conditions such as xeroderma
pigmentosum and nevoid basal cell carcinoma syndrome (De
Giorgi et al., 2005; Breen et al., 1975; Mulayim et al., 2002; Benedet
et al., 1997; Feakins and Lowe, 1997). Some cases have been associ-
ated with lichen sclerosus, implying chronic inﬂammation as a
Fig. 1. (Basal cell carcinoma, excisional biopsy from the vulva, scanning power): the
section from the excised specimen shows skin with an ulcerated multilobular epithelial
tumor comprised of basaloid cells arising from the epidermis and extending into the
superﬁcial dermis. Tumor extends to a peripheral margin. Hematoxylin and eosin 2.5×.
Fig. 2. (Basal cell carcinoma, excisional biopsy from the vulva, high power): there is
pleomorphism with cellular atypia, peripheral palisading, and retraction from a slightly
myxoid stroma, typical of basal cell carcinoma, nodular type.
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those reported in the literature had no known predisposing factors.
The presentation of vulvar BCC is variable. The lesions may simu-
late an inﬂammatory dermatosis, such as eczema or psoriasis, with
or without pruritus or other symptomotology, an infectious process,
such as chronic candidiasis (Nazari and Omranipour, 2006 Oct), or
may present as a palpable mass (Breen et al., 1975; Mulayim et al.,
2002; Benedet et al., 1997; Thomas et al., 1985). Other entities in
the clinical differential diagnosis of vulvar BCC include a site of chron-
ic ruptured folliculitis, trauma, melanocytic lesions, and benign or
malignant adnexal neoplasms. Histologically, the sample should be
large enough to differentiate BCC from adenoid cystic carcinoma, to
prevent unnecessary radical surgery (Lui et al., 2009). Because vulvar
BCC may simulate an inﬂammatory process, and the provider is not
accustomed to NMSC at this site, the symptomatology is often dis-
missed; thus, the diagnosis of vulvar BCC is frequently delayed
(Breen et al., 1975; Benedet et al., 1997; Feakins and Lowe, 1997).
In patients with darker skin tones, pigmentation is a frequent presen-
tation, simulating melanoma or seborrheic keratosis. In a Chinese
population of patients with vulvar BCC, 81% were pigmented (Lui et
al., 2009). The biologic behavior of BCC is that of a slow-growing
tumor which is locally invasive, but conﬁned to the dermis, allowing
deﬁnitive surgical treatment with local excision or destruction. Simi-
larly, vulvar BCC typically demonstrates a locally conﬁned tumor
(Breen et al., 1975; Mulayim et al., 2002; Asuman et al., 2008), but
there is a pattern of local recurrence in up to 20% of cases which is
thought to be a result of inadequate resection (De Giorgi et al.,
2005; Pisani et al., 2006; Mulayim et al., 2002; Asuman et al., 2008).
Metastatic disease is rare, on the order of 0.1% (Breen et al., 1975;
Mulayim et al., 2002; Asuman et al., 2008).
Metastatic vulvar BCC frequently goes to inguinal nodes, so it is
important to assess for adenopathy. Metastases have also included
the bone, lung, skin, and other sites (Suarez-Amor et al., 2009). The
genital site alone may predispose to an increased risk of metastasis,
but aggressive histologic subtypes (morpheaform, inﬁltrating and
basosquamous), large size of primary tumor (>2 cm) and absence
of UV-expose may also be associated with an increased chance of me-
tastasis (Suarez-Amor et al., 2009; Montegi et al., 2006).
The standard of care for treatment of BCC is wide local excision
with pathologically-proven clear margins of approximately 1 cm
(Pisani et al., 2006; Mulayim et al., 2002; Benedet et al., 1997;
Feakins and Lowe, 1997; Asuman et al., 2008). Postoperative radia-
tion does not appear to affect recurrence rate or overall survival
and is associated with unpleasant side effects and poor cosmetic re-
sults (Mulayim et al., 2002; Feakins and Lowe, 1997). Systemicchemotherapy is not indicated in the treatment of localized BCC,
though some evidence has suggested its use in metastatic disease
(Mulayim et al., 2002). Surgical excision remains the accepted treat-
ment for primary and recurrent localized vulvar BCC (Pisani et al.,
2006; Mulayim et al., 2002; Benedet et al., 1997; Feakins and Lowe,
1997; Asuman et al., 2008). Mohs micrographic surgery should be con-
sidered for challenging cases, especially if the tumor is recurrent, or if tis-
sue sparing is required to preserve critical anatomic sites, such as the
clitoris (Stiller et al., 1993).
This case illustrates the need for vigilance in the cutaneous exam
and awareness of the rare presentation of BCC in genital skin. It also
highlights the fact that young individuals and non-White patients
without chronic sun-exposure may rarely develop basal cell carcino-
ma. Early detection is critical to allow complete surgical cure; thus,
providers need to maintain a high index of suspicion and a low
threshold to biopsy any abnormality on the vulva.
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